{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T03:48:20Z","timestamp":1778644100199,"version":"3.51.4"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T00:00:00Z","timestamp":1749168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T00:00:00Z","timestamp":1749168000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s12325-025-03247-y","type":"journal-article","created":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T03:54:24Z","timestamp":1749182064000},"page":"3743-3761","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Drug Utilization, Adherence and Predictors of Drug-Changes and Discontinuation of Glaucoma Drug Therapies"],"prefix":"10.1007","volume":"42","author":[{"given":"Alessio","family":"Novella","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5462-1713","authenticated-orcid":false,"given":"Luciano","family":"Quaranta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Pasina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessia A.","family":"Galbussera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mauro","family":"Tettamanti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ida","family":"Fortino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivia","family":"Leoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert N.","family":"Weinreb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Nobili","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,6]]},"reference":[{"issue":"18","key":"3247_CR1","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1001\/jama.2014.3192","volume":"311","author":"RN Weinreb","year":"2014","unstructured":"Weinreb RN, Aung T, Medeiros FA. The pathophysiology and treatment of glaucoma: a review. JAMA. 2014;311(18):1901. https:\/\/doi.org\/10.1001\/jama.2014.3192.","journal-title":"JAMA"},{"issue":"11","key":"3247_CR2","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1016\/j.ophtha.2014.05.013","volume":"121","author":"YC Tham","year":"2014","unstructured":"Tham YC, Li X, Wong TY, Quigley HA, Aung T, Cheng CY. Global prevalence of glaucoma and projections of glaucoma burden through 2040. Ophthalmology. 2014;121(11):2081\u201390. https:\/\/doi.org\/10.1016\/j.ophtha.2014.05.013.","journal-title":"Ophthalmology"},{"issue":"6","key":"3247_CR3","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1001\/archopht.120.6.701","volume":"120","author":"MA Kass","year":"2002","unstructured":"Kass MA. The ocular hypertension treatment study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120(6):701. https:\/\/doi.org\/10.1001\/archopht.120.6.701.","journal-title":"Arch Ophthalmol"},{"issue":"7","key":"3247_CR4","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1016\/j.ophtha.2015.03.026","volume":"122","author":"PA Newman-Casey","year":"2015","unstructured":"Newman-Casey PA, Robin AL, Blachley T, et al. The most common barriers to glaucoma medication adherence. Ophthalmology. 2015;122(7):1308\u201316. https:\/\/doi.org\/10.1016\/j.ophtha.2015.03.026.","journal-title":"Ophthalmology"},{"issue":"5","key":"3247_CR5","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1007\/s40123-023-00730-z","volume":"12","author":"L Quaranta","year":"2023","unstructured":"Quaranta L, Novella A, Tettamanti M, Pasina L, Weinreb RN, Nobili A. Adherence and persistence to medical therapy in glaucoma: an overview. Ophthalmol Ther. 2023;12(5):2227\u201340. https:\/\/doi.org\/10.1007\/s40123-023-00730-z.","journal-title":"Ophthalmol Ther"},{"issue":"6","key":"3247_CR6","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/j.ophtha.2004.12.035","volume":"112","author":"C Olthoff","year":"2005","unstructured":"Olthoff C, Schouten J, Vandeborne B, Webers C. Noncompliance with ocular hypotensive treatment in patients with glaucoma or ocular hypertensionan evidence-based review. Ophthalmology. 2005;112(6):953-961.e7. https:\/\/doi.org\/10.1016\/j.ophtha.2004.12.035.","journal-title":"Ophthalmology"},{"issue":"2","key":"3247_CR7","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1097\/01.icu.0000193078.47616.aa","volume":"17","author":"JC Tsai","year":"2006","unstructured":"Tsai JC. Medication adherence in glaucoma: approaches for optimizing patient compliance. Curr Opin Ophthalmol. 2006;17(2):190\u20135. https:\/\/doi.org\/10.1097\/01.icu.0000193078.47616.aa.","journal-title":"Curr Opin Ophthalmol"},{"issue":"5","key":"3247_CR8","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1097\/00061198-200310000-00001","volume":"12","author":"JC Tsai","year":"2003","unstructured":"Tsai JC, McClure CA, Ramos SE, Schlundt DG, Pichert JW. Compliance barriers in glaucoma: a systematic classification. J Glaucoma. 2003;12(5):393\u20138. https:\/\/doi.org\/10.1097\/00061198-200310000-00001.","journal-title":"J Glaucoma"},{"issue":"4","key":"3247_CR9","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.ajo.2005.04.051","volume":"140","author":"BL Nordstrom","year":"2005","unstructured":"Nordstrom BL, Friedman DS, Mozaffari E, Quigley HA, Walker AM. Persistence and adherence with topical glaucoma therapy. Am J Ophthalmol. 2005;140(4):598\u2013606. https:\/\/doi.org\/10.1016\/j.ajo.2005.04.051.","journal-title":"Am J Ophthalmol"},{"key":"3247_CR10","doi-asserted-by":"publisher","unstructured":"European Glaucoma Society Terminology and Guidelines for Glaucoma, 4th Edition - Chapter 3: Treatment principles and options Supported by the EGS Foundation: Part 1: Foreword; Introduction; Glossary; Chapter 3 Treatment principles and options. Br J Ophthalmol. 2017;101(6):130\u2013195. https:\/\/doi.org\/10.1136\/bjophthalmol-2016-EGSguideline.003","DOI":"10.1136\/bjophthalmol-2016-EGSguideline.003"},{"issue":"6","key":"3247_CR11","doi-asserted-by":"publisher","first-page":"S93","DOI":"10.1016\/j.survophthal.2008.08.004","volume":"53","author":"A Alm","year":"2008","unstructured":"Alm A, Grierson I, Shields MB. Side effects associated with prostaglandin analog therapy. Surv Ophthalmol. 2008;53(6):S93\u2013105. https:\/\/doi.org\/10.1016\/j.survophthal.2008.08.004.","journal-title":"Surv Ophthalmol"},{"issue":"3","key":"3247_CR12","first-page":"233","volume":"26","author":"SC Patel","year":"1995","unstructured":"Patel SC, Spaeth GL. Compliance in patients prescribed eyedrops for glaucoma. Ophthalmic Surg. 1995;26(3):233\u20136.","journal-title":"Ophthalmic Surg"},{"key":"3247_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2025.03.025","author":"C Baudouin","year":"2025","unstructured":"Baudouin C, Myers JS, Van Tassel SH, et al. Adherence and persistence on prostaglandin analogues for glaucoma: a systematic review and meta-analysis. Am J Ophthalmol. 2025. https:\/\/doi.org\/10.1016\/j.ajo.2025.03.025.","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"3247_CR14","doi-asserted-by":"publisher","DOI":"10.1136\/bmjophth-2023-001607","volume":"9","author":"M Kolko","year":"2024","unstructured":"Kolko M, Faergemann Hansen R, Dal GL, et al. Predictors and long-term patterns of medication adherence to glaucoma treatment in Denmark\u2014an observational registry study of 30 100 Danish patients with glaucoma. BMJ Open Ophth. 2024;9(1): e001607. https:\/\/doi.org\/10.1136\/bmjophth-2023-001607.","journal-title":"BMJ Open Ophth."},{"issue":"1","key":"3247_CR15","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1159\/000521288","volume":"91","author":"ME Charlson","year":"2022","unstructured":"Charlson ME, Carrozzino D, Guidi J, Patierno C. Charlson Comorbidity Index: a critical review of clinimetric properties. Psychother Psychosom. 2022;91(1):8\u201335. https:\/\/doi.org\/10.1159\/000521288.","journal-title":"Psychother Psychosom"},{"issue":"12","key":"3247_CR16","doi-asserted-by":"publisher","first-page":"2398","DOI":"10.1016\/j.ophtha.2011.05.013","volume":"118","author":"B Sleath","year":"2011","unstructured":"Sleath B, Blalock S, Covert D, et al. The relationship between glaucoma medication adherence, eye drop technique, and visual field defect severity. Ophthalmology. 2011;118(12):2398\u2013402. https:\/\/doi.org\/10.1016\/j.ophtha.2011.05.013.","journal-title":"Ophthalmology"},{"issue":"Suppl 1","key":"3247_CR17","doi-asserted-by":"publisher","first-page":"S57","DOI":"10.1016\/j.survophthal.2008.08.002","volume":"53","author":"GF Schwartz","year":"2008","unstructured":"Schwartz GF, Quigley HA. Adherence and persistence with glaucoma therapy. Surv Ophthalmol. 2008;53(Suppl 1):S57-68. https:\/\/doi.org\/10.1016\/j.survophthal.2008.08.002.","journal-title":"Surv Ophthalmol"},{"issue":"4","key":"3247_CR18","doi-asserted-by":"publisher","first-page":"410","DOI":"10.5301\/EJO.2010.6112","volume":"21","author":"GCM Rossi","year":"2011","unstructured":"Rossi GCM, Pasinetti GM, Scudeller L, Radaelli R, Bianchi PE. Do adherence rates and glaucomatous visual field progression correlate? Eur J Ophthalmol. 2011;21(4):410\u20134. https:\/\/doi.org\/10.5301\/EJO.2010.6112.","journal-title":"Eur J Ophthalmol"},{"issue":"4","key":"3247_CR19","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.ophtha.2019.10.022","volume":"127","author":"PA Newman-Casey","year":"2020","unstructured":"Newman-Casey PA, Niziol LM, Gillespie BW, Janz NK, Lichter PR, Musch DC. The association between medication adherence and visual field progression in the collaborative initial glaucoma treatment study. Ophthalmology. 2020;127(4):477\u201383. https:\/\/doi.org\/10.1016\/j.ophtha.2019.10.022.","journal-title":"Ophthalmology"},{"issue":"12","key":"3247_CR20","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1097\/IJG.0000000000001943","volume":"30","author":"YH Shu","year":"2021","unstructured":"Shu YH, Wu J, Luong T, et al. Topical medication adherence and visual field progression in open-angle glaucoma: analysis of a large US Health Care System. J Glaucoma. 2021;30(12):1047\u201355. https:\/\/doi.org\/10.1097\/IJG.0000000000001943.","journal-title":"J Glaucoma"},{"key":"3247_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2020\/5901537","volume":"2020","author":"F Meier-Gibbons","year":"2020","unstructured":"Meier-Gibbons F, T\u00f6teberg-Harms M. Influence of cost of care and adherence in glaucoma management: an update. J Ophthalmol. 2020;2020:1\u20135. https:\/\/doi.org\/10.1155\/2020\/5901537.","journal-title":"J Ophthalmol"},{"issue":"4","key":"3247_CR22","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.preteyeres.2010.03.001","volume":"29","author":"C Baudouin","year":"2010","unstructured":"Baudouin C, Labb\u00e9 A, Liang H, Pauly A, Brignole-Baudouin F. Preservatives in eyedrops: The good, the bad and the ugly. Prog Retin Eye Res. 2010;29(4):312\u201334. https:\/\/doi.org\/10.1016\/j.preteyeres.2010.03.001.","journal-title":"Prog Retin Eye Res"},{"issue":"3","key":"3247_CR23","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1097\/IJG.0b013e31820bd2e1","volume":"21","author":"R Gupta","year":"2012","unstructured":"Gupta R, Patil B, Shah BM, Bali SJ, Mishra SK, Dada T. Evaluating eye drop instillation technique in glaucoma patients. J Glaucoma. 2012;21(3):189\u201392. https:\/\/doi.org\/10.1097\/IJG.0b013e31820bd2e1.","journal-title":"J Glaucoma"},{"issue":"12","key":"3247_CR24","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1016\/j.ophtha.2009.05.026","volume":"116","author":"CO Okeke","year":"2009","unstructured":"Okeke CO, Quigley HA, Jampel HD, et al. Interventions improve poor adherence with once daily glaucoma medications in electronically monitored patients. Ophthalmology. 2009;116(12):2286\u201393. https:\/\/doi.org\/10.1016\/j.ophtha.2009.05.026.","journal-title":"Ophthalmology"},{"issue":"4","key":"3247_CR25","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1038\/eye.2008.103","volume":"23","author":"J Lacey","year":"2009","unstructured":"Lacey J, Cate H, Broadway DC. Barriers to adherence with glaucoma medications: a qualitative research study. Eye (Lond). 2009;23(4):924\u201332. https:\/\/doi.org\/10.1038\/eye.2008.103.","journal-title":"Eye (Lond)"},{"issue":"11","key":"3247_CR26","doi-asserted-by":"publisher","first-page":"5052","DOI":"10.1167\/iovs.07-0290","volume":"48","author":"DS Friedman","year":"2007","unstructured":"Friedman DS, Quigley HA, Gelb L, et al. Using pharmacy claims data to study adherence to glaucoma medications: methodology and findings of the Glaucoma Adherence and Persistency Study (GAPS). Invest Ophthalmol Vis Sci. 2007;48(11):5052\u20137. https:\/\/doi.org\/10.1167\/iovs.07-0290.","journal-title":"Invest Ophthalmol Vis Sci"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03247-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03247-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03247-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T19:03:17Z","timestamp":1754334197000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03247-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,6]]},"references-count":26,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["3247"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03247-y","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,6]]},"assertion":[{"value":"3 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Luciano Quaranta is an Editorial Board member of Advances in Therapy. Luciano Quaranta was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Alessio Novella: has nothing to disclose. Luciano Quaranta: has nothing to disclose. Luca Pasina: has nothing to disclose. Alessia A. Galbussera: has nothing to disclose. Mauro Tettamanti: has nothing to disclose. Ida Fortino: has nothing to disclose. Olivia Leoni: has nothing to disclose. Robert N. Weinreb: has nothing to disclose. Alessandro Nobili: has nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"According to the Italian law, studies using anonymous data from administrative databases that do not involve direct access to individual patient data need no approval from or notification by an ethics committee\/institutional review board, and informed patient consent is not required. All data were managed according to Italian law on privacy.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}